Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

Second quarter Net Product Sales of $36.0 million, which increased from $31.8 million for the same period in 2023 $108.0 to $116.0 million $107.0 to $111.0 million $(22.0) to $3.0 million $(10.0) to $3.0 million ZYNRELEF® Vial Access Needle ("VAN") PDUFA goal date set for September 23, 2024 ZYNRELEF included in the proposed 2025 Non-Opioid Policy for Pain Relief ("NOPAIN Act") SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biote ...